Wastewater-based surveillance (WBS) has undergone dramatic advancement in the context
of the coronavirus disease 2019 (COVID-19) pandemic. The power and potential of this …

The route of administration of a therapeutic agent has a substantial impact on its success.
Therapeutic antibodies are usually administered systemically, either directly by intravenous …

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading
cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in …

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early
childhood and palivizumab is the only licensed intervention for prevention. Palivizumab …

Monoclonal antibodies (mAbs) and their derivatives have achieved remarkable success as
medicine, targeting both diagnostic and therapeutic applications associated with …

Background: For the past two decades, there has been a huge expansion in the
development of therapeutic antibodies, with 6 to 10 novel entities approved each year …

In late 2019, a new member of the Coronaviridae family, officially designated as “severe
acute respiratory syndrome coronavirus 2”(SARS-CoV-2), emerged and spread rapidly. The …

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract
infections (LRTIs) in infants worldwide. The global direct medical cost associated with RSV …

Rationale: Studies of the immune responses at the site of respiratory syncytial virus (RSV)
infection are sparse despite nearly five decades of research into understanding RSV …

Background Since the widespread adoption of palivizumab prophylaxis in Europe, there
have been a number of clinical practice guidelines (CPGs) published for the prevention of …